Delving into the Latest Updates on Shanghai Aibo Pharmaceutical Technology Co Ltd with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Endocrinology and Metabolic Disease

Chemical drugs

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Endocrinology and Metabolic Disease	2
Neoplasms	2
Nervous System Diseases	1

Top 5 Drug Type	Count

Chemical drugs	2
Small molecule drug	1

主要目的：评价超重/肥胖受试者多次口服ABP2111Na片的安全性和耐受性；次要目的： 1）评价超重/肥胖受试者多次口服ABP2111Na片的药代动力学（PK）特征； 2）评价超重/肥胖受试者多次口服ABP2111Na片药效动力学（PD）； 3）初步探索ABP2111Na片控制体重的有效性，为后期临床研究提供依据； 4）初步评估ABP2111Na片在超重/肥胖受试者的心脏安全性，包括校正QT间期（QTc）延长的可能性，并评估PK/QTc关系。

[Translation]

Main purpose: Evaluate the safety and tolerability of ABP2111Na tablets after multiple oral administration in overweight/obese subjects; Secondary purposes: 1) Evaluate the pharmacokinetic (PK) characteristics of ABP2111Na tablets after multiple oral administration in overweight/obese subjects; 2) Evaluate the pharmacodynamics (PD) of ABP2111Na tablets after multiple oral administration in overweight/obese subjects; 3) Preliminarily explore the effectiveness of ABP2111Na tablets in controlling body weight and provide a basis for later clinical studies; 4) Preliminarily evaluate the cardiac safety of ABP2111Na tablets in overweight/obese subjects, including the possibility of correcting the QT interval (QTc) prolongation, and evaluate the PK/QTc relationship.

Start Date-

Sponsor / Collaborator

Shanghai Aibo Pharmaceutical Technology Co Ltd

CTR20240447 / Not yet recruitingPhase 1

一项在晚期实体瘤患者中评估ABP1019A片的安全性、耐受性、药代动力学特征和初步疗效的剂量递增及扩展队列的开放性I/II期临床研究

[Translation] An open-label Phase I/II clinical study with dose escalation and expansion cohorts to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of ABP1019A tablets in patients with advanced solid tumors

（一）I期研究目的 1、主要研究目的评估ABP1019A片在晚期实体瘤患者中的安全性和耐受性；确定后继临床试验推荐剂量（RP2D）以及给药方案。 2、次要研究目的研究ABP1019A片单次和多次给药在晚期实体瘤患者中的药代动力学（PK）特征；初步评估ABP1019A片的心脏安全性，包括校正QT间期（QTc）延长的可能性，并评估PK/QTc关系；初步评估ABP1019A片治疗晚期实体瘤的有效性。（二）II期研究目的 1、主要研究目的初步评估ABP1019A片在目标晚期实体瘤患者中的有效性。 2、次要研究目的评估ABP1019A片在目标晚期实体瘤患者中的安全性。

[Translation]

(I) Objectives of Phase I Study 1. Primary Objectives To evaluate the safety and tolerability of ABP1019A tablets in patients with advanced solid tumors; to determine the recommended dose (RP2D) and dosing regimen for subsequent clinical trials. 2. Secondary Objectives To study the pharmacokinetic (PK) characteristics of single and multiple doses of ABP1019A tablets in patients with advanced solid tumors; To preliminarily evaluate the cardiac safety of ABP1019A tablets, including the possibility of correcting QT interval (QTc) prolongation, and to evaluate the PK/QTc relationship; To preliminarily evaluate the effectiveness of ABP1019A tablets in the treatment of advanced solid tumors. (II) Objectives of Phase II Study 1. Primary Objectives To preliminarily evaluate the effectiveness of ABP1019A tablets in target patients with advanced solid tumors. 2. Secondary Objectives To evaluate the safety of ABP1019A tablets in target patients with advanced solid tumors.

Start Date-

Sponsor / Collaborator

Shanghai Aibo Pharmaceutical Technology Co Ltd

CTR20242948 / Not yet recruitingPhase 1

一项在晚期恶性实体瘤患者中评估ABP1618片的安全性、耐受性、药代动力学特征和初步疗效的剂量递增及扩展队列的I/II期临床研究

[Translation] A Phase I/II clinical study with dose escalation and expansion cohorts to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of ABP1618 tablets in patients with advanced malignant solid tumors

（一）I期研究目的 1、主要研究目的评估ABP1618片在晚期实体瘤患者中的安全性和耐受性；确定后继临床试验推荐剂量（RP2D）以及给药方案。 2、次要研究目的研究ABP1618片单次和多次给药在晚期实体瘤患者中的药代动力学（PK）特征；初步评估ABP1618片的心脏安全性，包括校正QT间期（QTc）延长的可能性，并评估PK/QTc关系；初步评估ABP1618片治疗晚期实体瘤的有效性。（二）II期研究目的 1、主要研究目的初步评估ABP1618片在目标晚期实体瘤患者中的有效性。 2、次要研究目的评估ABP1618片在目标晚期实体瘤患者中的安全性。

[Translation]

(I) Objectives of Phase I Study 1. Primary Objectives To evaluate the safety and tolerability of ABP1618 tablets in patients with advanced solid tumors; to determine the recommended dose (RP2D) and dosing regimen for subsequent clinical trials. 2. Secondary Objectives To study the pharmacokinetic (PK) characteristics of single and multiple doses of ABP1618 tablets in patients with advanced solid tumors; To preliminarily evaluate the cardiac safety of ABP1618 tablets, including the possibility of correcting QT interval (QTc) prolongation, and to evaluate the PK/QTc relationship; To preliminarily evaluate the effectiveness of ABP1618 tablets in the treatment of advanced solid tumors. (II) Objectives of Phase II Study 1. Primary Objectives To preliminarily evaluate the effectiveness of ABP1618 tablets in target patients with advanced solid tumors. 2. Secondary Objectives To evaluate the safety of ABP1618 tablets in target patients with advanced solid tumors.

Start Date-

Sponsor / Collaborator

Shanghai Aibo Pharmaceutical Technology Co Ltd

100 Clinical Results associated with Shanghai Aibo Pharmaceutical Technology Co Ltd

Login to view more data

0 Patents (Medical) associated with Shanghai Aibo Pharmaceutical Technology Co Ltd

Login to view more data

100 Deals associated with Shanghai Aibo Pharmaceutical Technology Co Ltd

Login to view more data

100 Translational Medicine associated with Shanghai Aibo Pharmaceutical Technology Co Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

2

1

Phase 2 Clinical

Login to view more data